SCHEMBL5165447

SCHEMBL5165447

c1cc(N2CCOCC2)ccc1C1CCOCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
MAPT P10636 4/20 0.50
MEN1 O00255 2/20 0.50
HTT P42858 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
KDM4E B2RXH2 3/20 0.48
ALOX15 P16050 2/20 0.48
HSD17B10 Q99714 2/20 0.48
USP2 O75604 1/20 0.48
TP53 P04637 1/20 0.48
MAPK1 P28482 1/20 0.48
GRM2 Q14416 1/20 0.48
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
LGMN Q99538 1/20 0.44
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4461599 0.90 HRH3 (0.50) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL30700722 0.90 HRH3 (0.47) ALDH1A1MAPTMEN1HTTKMT2A
Hydrochloric Acid SCHEMBL31308866 0.89 HRH3 (0.46) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL8038871 0.85 QDPR (0.47) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL19139501 0.85 SIGMAR1 (0.48) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL4480849 0.82 HRH3 (0.43) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL4470001 0.82 HRH3 (0.43) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL9093746 0.80 LMNA (0.71) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL10162461 0.79 HTR3A (0.53) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL10161185 0.79 GRM2 (0.45) ALDH1A1MAPTMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768975-A2 PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS Pfizer Products Inc. (US) 2007-04-04 EP disclosed
WO-2006106416-A1 PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN PFIZER PRODUCTS INC. (US) 2006-10-12 WO disclosed
US-20060025421-A1 Pyridyl piperazines for the treatment of CNS disorders PFIZER INC 2006-02-02 US disclosed
WO-2006000912-A2 PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS PFIZER PRODUCTS INC. (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025421-A1 Pyridyl piperazines for the treatment of CNS disorders TPH2, HTR1A, TPH1 ALDH1A1 383/4885MAPT 1058/4885MEN1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.